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≤1mm. The shorter treatment delivery was superior for three 
patterns, while the longer treatment was preferred in the 
case of temporal displacement of the prostate. 
 
Conclusion: The treatment time for extreme 
hypofractionation of prostate cancer is reduced to less than 
half the time per fraction by combining FFF-technique with 
VMAT. The treatment plan quality was preserved for the FFF 
beams. Finally, a shorter beam-on time also seems 
advantageous for the majority of prostate motion patterns 
investigated. 
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Purpose or Objective: With increased 5 years survival of 
children with medulloblastoma, optimization of radiotherapy 
treatment to avoid iatrogenic sequelae has become a primary 
issue. Clinical and dosimetric characteristics of VMAT 
Craniospinal Irradiation (CSI) were studied and compared 
with the 3DCRT technique in use since 1997 at our institution 
with excellent clinical results. The impact of a setup error on 
dose distribution was also studied. 
 
Material and Methods: CT images of 8 pts that received CSI 
at our institution (23.4 Gy in 13 fractions) were used for the 
dosimetric study. For each patient, a standard 3DCRT 
treatment and a VMAT were planned. PTV dosimetric 
objectives for treatment planning were: D95% >95%, D100% 
>90%, D5% <107%. The resulting DVHs were analyzed 
considering: conformity index (CI) and homogeneity index 
(HI) for PTV, mean dose (Dmean) and D2% for OARs (small 
bowel, kidneys, heart, liver, stomach, lenses, thyroid, lungs) 
and V2Gy of non target tissues as an integral dose index. The 
data were then compared using paired Student’s t test. The 
dependence of dose indexes on patient size was evaluated. A 
3 mm longitudinal error in patient setup was simulated for 
both techniques to evaluate dosimetric impact in the 
junction region. 
 
Results: Dosimetric objectives were always met. All VMAT 
treatment plans had better HI and CI independently of 
patient size. Dmean and D2% of heart and thyroid were 
significantly lower with VMAT. On average, for heart Dmean 
was 9.8±3.4 Gy and 6.3±1.0 Gy, and D2% was 20.3±4.1Gy and 
10.4±1.7 Gy, for 3DCRT and VMAT respectively, while for 
thyroid Dmean was 18.2±1.2 Gy and 13.8±1.8 Gy, and D2% 
was 20.4±1.2 Gy and 17.4±2.0 Gy, for 3DCRT and VMAT 
respectively. On the contrary, lung dose was higher with 
VMAT: on average Dmean was 1.8±0.9 Gy for 3DCRT and 
3.5±0.8 Gy for VMAT. A 3 mm gap at field junction level 
resulted in an underdosage of about 20% for VMAT and 50% 
for 3DCRT, while a 3 mm overlap gave rise to a hotspot on 
the spine up to 30% for VMAT and 70% for 3DCRT. V2Gy was 
about 3 times higher for VMAT. 
 
Conclusion: VMAT allowed to achieve a more conformal and 
homogeneous dose distribution, with greater sparing of most 
OARs. Considering the risk of iatrogenic cardiopathy, 
hypothyroidism or secondary tumors to the thyroid, the dose 
reduction obtained with VMAT was significant. The clinical 
effect of the increased lung dose is not yet predictable, since 
absolute dose values were extremely low. VMAT implies a 
higher MU value for the delivery of the prescribed dose, 
possibly increasing the risk of secondary tumors. This is an 
important factor when dealing with pediatric pts. In VMAT, 
overdosage areas are greatly reduced with respect to 3DCRT, 
particularly in the junction region. The analysis of simulated 
gaps and overlaps shows that field junctions are less critical 
for VMAT, nevertheless junction moving is still mandatory to 
avoid potentially dangerous hot or cold spots. Partially 
supported by Associazione Italiana per la Ricerca sul Cancro 
(AIRC) 
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Purpose or Objective: GTV-based prescription has been 
proposed as a possible recipe for Monte Carlo treatment 
planning in Cyberknife SBRT treatments for lung lesions 
(Lacornerie et al., 2014, [1]). The feasibility of this approach 
was investigated comparing Ray-Tracing algorithm (Effective 
Path Length method, EPL) and Monte Carlo (MC) dose 
calculation. 
 
Material and Methods: A group of 40 consecutive patients 
from July to October 2015, treated with Cyberknife SBRT 
using an advanced target tracking system (Lung Optimized 
Treatment, LOT) was considered. Primary lung cancers and 
metastatic pulmonary lesions, different tumor size (small: 
V<14cc, large: V>65cc) and locations (totally air-surrounded, 
partially air-surrounded), prescription dose and fractionation 
schemes were included in the group. Treatment plans were 
optimized using RT algorithm (RT plans), with prescription 
isodose line of 80% providing 95% PTV coverage (PTV = GTV + 
5mm), and re-calculated with MC algorithm (1x1x1 mm3 dose 
grid, uncertainty=1%), using the same beam angles and 
monitor units (MCrecalc plans). Dose parameters for RT and 
MCrecalc plans were evaluated for both GTV, PTV and OARs, 
in relation to tumor size and position. On a subset of 5 
patients, MCrecalc plans were normalized to the isodose line 
encompassing the 95% of the GTV volume (MCnorm plans) and 
compared to MC-optimized plans, with dose prescribed to the 
same isodose line (MCopt plans). 
 
Results: Difference between RT and MCrecalc plans in 
average percentage volume covered by the prescribed dose 
for GTV and PTV is 13.5% (RT: 99.6%, MC: 86.1%) and 41.8% 
(RT: 96.8%, MC: 55.0%) respectively. Dose parameters 
referred to GTV (Dmean, D50, D98, D2) have a lower 
variation compared with PTV parameters: excluding D2, D50 
shows the lowest variability for the analyzed group. 
Concerning OARs, difference in V20, V10, V5 for lungs 
(ipsilateral and contralateral) is 0.6%, 1.4% and 3.4%, 
respectively.  
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MCnorm and MCopt have a value of GTV D50 and Dmean 
comparable to the RT plan and higher than the MCrecalc 
plan. At the same time, MCnorm plans could not always be 
accepted referring to OARs dose constraints respect and 
target dose conformity (see Fig.1). Results are reported in 
Table 1. 
 
 
Conclusion: Lower variation of GTV dose parameters 
compared with PTV, when both RT and MCrecalc treatment 
plans are evaluated, suggests that GTV should be used for 
dose normalization and reporting instead of PTV. According 
to van der Voort van Zyp et al. (2010, [2]), a different 
prescription dose could be adopted, depending on lesion size 
and location. Moreover, MCopt plans need to be 
implemented, adopting a different prescription dose based 
on GTV D50 and Dmean values [1], as MCnorm plans could not 
guarantee appropriate target coverage and OARs sparing. 
Further multivariate analysis is mandatory to determine if 
there are correlations between the variables (size and 
location of the lesions, type of tracking adopted) considered 
for plan comparisons. 
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Purpose or Objective: To develop a dysphagia optimised 
IMRT (Do-IMRT) technique comparing fixed-field IMRT with 
VMAT for treatment of head and neck cancer in the DARS 
clinical trial (CRUK/14/014), which is a phase III randomised 
multicentre study of Do-IMRT versus standard IMRT (S-IMRT). 
 
Material and Methods: Six oropharynx cases were outlined 
and planned according to the DARS trial QA guidelines. CTVs 
were outlined using a volumetric approach with a 10mm GTV-
CTV expansion. Pharyngeal constrictor muscles (PCM) were 
also delineated. The dose levels prescribed were 65 Gy to the 
primary site and involved nodes and 54 Gy to the elective 
volume in 30 fractions. Plans were produced according to 
both arms of the trial using both fixed-field IMRT and VMAT 
(RapidArc) with an Eclipse treatment planning system 
(version 11). In the experimental Do-IMRT arm, the aim was 
to achieve a mean dose of less than 50 Gy to the superior and 
middle PCMs, excluding the CTV receiving 65 Gy 
(PlanSMPCM), and less than 20 Gy to the similarly edited 
inferior PCM (PlanIPCM). These constraints were prioritised 
over coverage of the PTV receiving 54 Gy (PTV_5400) but not 
the PTV receiving 65 Gy (PTV_6500). In the S-IMRT arm no 
attempt was made to reduce PCM doses. Plans were assessed 
for their clinical acceptability and DVH statistics compared. 
 
Results: Using fixed-field IMRT for Do-IMRT, it was not 
possible to achieve clinically acceptable plans in terms of 
both PTV_5400 95% isodose coverage and homogeneity whilst 
achieving the PCM constraints. However, using VMAT for Do-
IMRT a PlanSMPCM mean dose of less than 50 Gy was 
achieved in all cases, reduced by 8 Gy on average compared 
to S-IMRT. PlanIPCM mean doses of less than 20 Gy were 
achieved in the majority of cases, reduced by 30 Gy on 
average compared to S-IMRT. Do-IMRT plans had decreased 
but acceptable dose homogeneity and 95% isodose coverage 
was maintained, only compromising in the region where PCMs 
and PTV_5400 overlap (as shown in the example in figure 1). 
Other OAR (spinal cord, brainstem and parotids) doses were 
increased for Do-IMRT but critical OAR constraints were still 
achieved in all cases. The results are summarised in table 1. 
 
 
 
Figure 1: Dose distribution (colour wash displays 95-107% of 
54 Gy) of transverse slice showing PTV_5400 (blue) coverage 
using S-IMRT (left) compared to Do-IMRT (right), where 
